

SOP: PRE-REVIEW

Document No.:	Edition No.:	Effective Date:	Page:
CM-101	001	1 May 2015	Page 1 of 3

1. PURPOSE

- 1.1. This procedure establishes the process to review IRB submissions for regulatory issues.
- 1.2. This procedure begins when an IRB submission for a review or determination has been checked by office staff.
- 1.3. This procedure ends when the <Pre-Reviewer> has completed the review or an investigator has withdrawn the submission.

2. POLICY

- 2.1. As part of IRB review, all submissions are reviewed by a <Pre-Reviewer> to:
 - 2.1.1. Identify submissions with missing materials
 - 2.1.2. Identify and document the determinations that the IRB needs to make in order to approve research. (For example. waiver of consent, children, prisoners)
 - 2.1.3. Identify, make, and document regulatory determinations that the institution needs to make in order to approve research (For example, IND/IDE requirements)
 - 2.1.4. Identify any relevant local, state, or international requirements
 - 2.1.5. Arrange for consultation to resolve local, state, or international requirements.
 - 2.1.6. Identify other special review issues.
 - 2.1.7. Determine the likely level of review (<Committee Review> versus <Non-committee Review>)
- 2.2. The <Pre-Reviewer> documents <Pre-Review> findings.
- 2.3. The <Meeting Chair> ensures that issues raised by <Pre-Review> are covered at meetings.
- 2.4. The addition of a site to a previously approved study is considered a modification to previously approved research.
- 2.5. Changes to study personnel are not considered a modification to previously approved research when the study personnel meet the qualifications described in the IRB approved study.

3. RESPONSIBILITY

- 3.1. <Pre-Reviewers> carry out these procedures.

4. PROCEDURE

- 4.1. If the submission is limited to an updated list of study personnel, notify the submitter and take no further action.
- 4.2. If the submission is a request to transfer the study to another IRB, transfer the study and notify the investigator.
- 4.3. If the investigator is <Restricted> and the submission satisfies all outstanding delinquent submissions, remove the investigator's <Restricted> status.
- 4.4. If the investigator is <Restricted> and the submission is an initial submission, notify the submission contact of IRB policy to disapprove those submissions:

SOP: PRE-REVIEW

Document No.:	Edition No.:	Effective Date:	Page:
CM-101	001	1 May 2015	Page 2 of 3

- 4.4.1. If the submission contact wants to address the <Restricted> status, have the contact provide additional information as appropriate to resolve the issues, or withdraw the submission and resubmit when complete.
- 4.4.2. If the submission contact does not want to address the <Restricted> status, note this and continue processing.
- 4.5. If the submission is a response to a decision to require modifications in order to approve research:
 - 4.5.1. Evaluate whether the submitter made the required modifications.
 - 4.5.2. If the submitter made the required modifications and no others, issue an approval. Otherwise, process as a modification.
- 4.6. Determine whether the submission is initial, continuing, or modification. If both continuing and modification, follow both procedures.
 - 4.6.1. For initial submission:
 - 4.6.1.1 Document any <Pre-Review> findings.
 - 4.6.2. For a modification submission:
 - 4.6.2.1 Review the <Pre-Review> findings associated with prior approval(s).
 - 4.6.2.2 Update <Pre-Review> findings as needed.
 - 4.6.2.3 Determine whether the submission includes information that might represent an <Unanticipated Problem Involving Risks to Subjects or Others>, <Serious Noncompliance>, <Continuing Noncompliance>, <Suspension of IRB Approval>, or <Termination of IRB Approval>.
 - 4.6.3. For continuing submission:
 - 4.6.3.1 If the submission meets the criteria, close the study, and notify the investigator.
 - 4.6.3.2 Review the <Pre-Review> findings associated with prior approval(s).
 - 4.6.3.3 Update <Pre-Review> findings as needed.
 - 4.6.3.4 Check whether consent document(s) and script(s) being used are the currently approved versions.
 - 4.6.3.5 Determine whether the submission includes information that might represent an <Unanticipated Problem Involving Risks to Subjects or Others>, <Serious Noncompliance>, <Continuing Noncompliance>, <Suspension of IRB Approval>, or <Termination of IRB Approval>.
- 4.7. Identify any relevant local, state, or international requirements related to human research.

SOP: PRE-REVIEW

Document No.:	Edition No.:	Effective Date:	Page:
CM-101	001	1 May 2015	Page 3 of 3

- 4.7.1. Arrange for consultation, if needed to resolve local, state, or international regulatory issues.
- 4.8. Communicate with the submission contact for any potentially resolvable contingencies.
 - 4.8.1. If the submission contact wants to address the contingencies, have the contact provide additional information as appropriate to resolve the issues, or withdraw the submission and resubmit when complete.
 - 4.8.2. If the submission contact does not want to address the contingencies, note this and continue processing.
- 4.9. Determine whether the likely level of review is <Non-Committee Review> or <Committee Review> and route appropriately.

5. REFERENCES

- 5.1. None